Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Equities

CRNO B

SE0008241558

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2023-06-19 pm EDT			5-day change	1st Jan Change
0.521 ^SEK	-7.13%		+7.98%	-76.90%

Apr. 16	Cereno Scientific AB Approves Election of New Directors	CI
Apr. 11	Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	MT

Cereno Scientific AB Receives FDA IND Acceptance and Made the Final Preparations for Its Phase Ii Clinical Trial with Cs1 in Patients with Pulmonary Arterial Hypertension

January 12, 2022 at 02:33 am EST

Cereno Scientific AB (publ) received FDA IND acceptance and made the final preparations for its phase II clinical trial with CS1 in patients with pulmonary arterial hypertension. Cereno also broadened and powered up its development portfolio through collaboration agreements with the University of Michigan to bring two preclinical programmes through IND acceptance. BioStock spoke with the company's CEO Sten R. Sörensen to get his thoughts on the eventful past year and his expectations for 2022.

Latest news about Cereno Scientific AB (publ)

Cereno Scientific AB Approves Election of New Directors	Apr. 16	CI
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	Apr. 11	MT
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment	Apr. 10	MT
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014	Apr. 10	CI
Cereno Scientific Receives Patent Expansion in Europe	Apr. 09	MT
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate	Mar. 22	MT
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH	Mar. 21	CI
Cereno Scientific Appoints Don De Bethizy as Board of Directors	Mar. 14	CI
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH	Mar. 06	CI
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH	Feb. 29	CI
Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH	Feb. 21	CI
Sweden's Cereno Scientific Appoints Chief Medical Officer	Feb. 13	MT
Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D	Feb. 13	CI
Cereno Scientific AB Appoints Julia Fransson as Director of Business Development	Feb. 02	CI
Cereno Scientific AB Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities	Feb. 01	CI
Cereno Scientific Gets US FDA Approval for Expanded Access to Drug Candidate	Jan. 31	MT
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension	Jan. 31	CI
Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director	Jan. 12	CI
Cereno Scientific Pens Contact with CordenPharma for Scaled Manufacturing of Hypertension Drug	Jan. 11	MT
Cereno Scientific Submits Request to the FDA for "Compassionate Use" of CS1 for Treatment of Patients with Rare Disease Pulmonary Arterial Hypertension	Jan. 04	CI
Cereno Scientific Seeks US FDA Nod for Compassionate Use of Investigational Drug CS1	Jan. 04	MT
Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH	Dec. 21	CI
Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting	Dec. 13	CI
Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585	Dec. 12	CI

Chart Cereno Scientific AB (publ)

Duration

Period

More charts

Company Profile

Cereno Scientific AB is a manufacturer of pharmaceutical preparation. The Company was founded in 1970 and is located in Gothenburg, Sweden.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+0.47%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.28%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs

Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Equities

CRNO B

SE0008241558

Biotechnology & Medical Research

Cereno Scientific AB Receives FDA IND Acceptance and Made the Final Preparations for Its Phase Ii Clinical Trial with Cs1 in Patients with Pulmonary Arterial Hypertension

Latest news about Cereno Scientific AB (publ)

Chart Cereno Scientific AB (publ)

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs